PMID: 11314675Apr 21, 2001Paper

Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats

Psychopharmacology
E A Walker, A M Young

Abstract

Repeated treatment experiments with high and low efficacy agonists provide critical insight into possible mechanisms underlying development of opioid tolerance. Experiments in a tail-withdrawal assay tested the hypothesis that magnitude of tolerance to antinociceptive effects is inversely related to agonist relative efficacy in rats intermittently treated with etonitazene. morphine, or buprenorphine. The antinociceptive effects of five mu opioid agonists were tested in male, Sprague-Dawley rats in a warm-water tail-withdrawal assay. To induce tolerance, escalating doses of the higher efficacy agonist etonitazene, the high efficacy agonist morphine, or the lower efficacy agonist buprenorphine were administered twice daily for 2-8 weeks. Etonitazene, etorphine, morphine, buprenorphine, and GPA 1657 [(1)-beta-2'-hydroxy-2,9-dimethyl-5-phenyl-6,7-benzomorphan] produced dose-dependent increases in tail-withdrawal latency until 100% maximum possible effect (%MPE) was obtained. Treatment with escalating doses of etonitazene, morphine, or buprenorphine produced greater tolerance to the lower efficacy agonists buprenorphine and GPA 1657 than to the higher efficacy agonists etonitazene, etorphine, and morphine. Treatment with buprenorphi...Continue Reading

Citations

Mar 31, 2006·Psychopharmacology·Gisela GreckschThomas Koch
Oct 10, 2009·Psychopharmacology·Priyanka A MadiaByron C Yoburn
Jun 11, 2005·Pharmacology, Biochemistry, and Behavior·R GaliciC P France
Jan 22, 2003·Peptides·Richard J Bodnar, Maria M Hadjimarkou
Jun 22, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sandra D ComerWilliam J Kowalczyk
Aug 4, 2001·Behavioural Pharmacology·M Rodríguez-AriasV M Simón
Nov 1, 2002·Behavioural Pharmacology·S S NegusM R Brandt
Nov 6, 2010·The Journal of Pharmacology and Experimental Therapeutics·Carol A Paronis, Jack Bergman
Jan 17, 2008·Molecular Pharmacology·Michael S Virk, John T Williams
Jan 17, 2013·Pharmacological Reviews·John T WilliamsMacdonald J Christie
Jun 6, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Michael S VirkJohn T Williams
Mar 6, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Anuradha MadhavanJennifer L Whistler
Mar 25, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Nidia QuillinanJohn T Williams
Jun 10, 2011·EMBO Molecular Medicine·Amy Chang Berger, Jennifer L Whistler
Mar 3, 2009·Pharmacology, Biochemistry, and Behavior·Shveta V DigheByron C Yoburn
Jun 26, 2012·British Journal of Pharmacology·Christian DollStefan Schulz
Dec 1, 2010·European Journal of Pharmacology·Elzbieta P Wala, Joseph R Holtman
Jul 22, 2008·Pharmacology, Biochemistry, and Behavior·Sunil SirohiByron C Yoburn
Dec 11, 2007·Current Opinion in Neurobiology·Lene Martini, Jennifer L Whistler
Mar 15, 2002·Cell·Brigitte L Kieffer, Christopher J Evans
Jan 21, 2019·Addiction·Adam Bisaga
May 4, 2010·Annals of Neurology·Amy Chang Berger, Jennifer L Whistler
Sep 8, 2005·The Journal of Pharmacology and Experimental Therapeutics·Sandra D ComerEllen A Walker
Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Ellen A Walker, Alice M Young
Jun 28, 2003·Natural Product Reports·Kenneth W Bentley
Mar 26, 2011·British Journal of Pharmacology·Michael M Morgan, MacDonald J Christie
Dec 12, 2018·Neuroscience and Biobehavioral Reviews·Sandra D Comer, Catherine M Cahill

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.